Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
April 17, 2019 at 16:05 PM EDT
BERKELEY, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced that abstracts pertaining to the company’s lead programs, STING agonist ADU-S100 and anti-APRIL antibody BION-1301, will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.
Details of the oral presentation are as follows:
Details of the poster presentations are as follows:
Cautionary Note on Forward-Looking Statements